Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460128 | 0.97 | ENPP1 (0.48) | ENPP1P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL1433847 | 0.84 | ENPP1 (0.46) | ENPP1P2RY2P2RY4P2RY6 | |
| Triphosphate SCHEMBL869856 | 0.78 | ENPP1 (0.51) | ENPP1P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL20798160 | 0.77 | ENPP1 (0.43) | ENPP1P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL1452492 | 0.74 | POLB (0.44) | POLA1 | |
| SCHEMBL3364511 | 0.74 | POLB (0.44) | POLA1 | |
| SCHEMBL4816453 | 0.74 | P2RY6 (0.36) | P2RY2P2RY6POLA1 | |
| SCHEMBL446614 | 0.72 | POLA1 (0.35) | ENPP1P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL10496372 | 0.71 | POLG (0.47) | P2RY2P2RY4P2RY6 | |
| SCHEMBL76047 | 0.71 | POLG (0.47) | P2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 981 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115427586-B | Recovery phase in large-scale parallel sequencing | 深圳华大智造科技股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| EP-4121554-B1 | RESTORING PHASE IN MASSIVELY PARALLEL SEQUENCING | MGI TECH CO LTD (CN) | 2024-10-30 | — | — | EP | claimed |
| US-20230129228-A1 | RESTORING PHASE IN MASSIVELY PARALLEL SEQUENCING | MGI TECH CO., LTD. (CN) | 2023-04-27 | — | — | US | claimed |
| EP-4121554-A1 | RESTORING PHASE IN MASSIVELY PARALLEL SEQUENCING | MGI Tech Co., Ltd. (CN) | 2023-01-25 | — | — | EP | claimed |
| CN-115427586-A | Recovery phase in massively parallel sequencing | 深圳华大智造科技股份有限公司 | 2022-12-02 | — | — | CN | claimed |
| WO-2021188906-A1 | NOVEL MRNA-BASED COVID-19 MULTI-VALENT VACCINE AND METHODS OF SCALED PRODUCTION OF THE SAME | NATURE'S TOOLBOX, INC. (US) | 2021-09-23 | — | — | WO | claimed |
| US-10407703-B2 | Means and methods for producing Neisseria meningitidis capsular polysaccharides of low dispersity | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2019-09-10 | — | — | US | claimed |
| US-9066866-B2 | Direct cellular energy delivery system | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-06-30 | — | — | US | claimed |
| WO-2013112358-A1 | LUCIFERASE-LINKED METHODS FOR DETECTING ADENOSINE AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-08-01 | — | — | WO | claimed |
| EP-0833936-A4 | ALTERNATIVE DYE-LABELED PRIMERS, RIBONUCLEOTIDES, DEOXYRIBONUCLEOTIDES, AND DIDEOXYRIBONUCLEOTIDES FOR AUTOMATED DNA ANALYSIS AND HOMOGENEOUS AMPLIFICATION/DETECTION ASSAYS | BAYLOR COLLEGE MEDICINE (US) | 2005-03-02 | — | — | EP | claimed |
| EP-0833936-A1 | ALTERNATIVE DYE-LABELED PRIMERS, RIBONUCLEOTIDES, DEOXYRIBONUCLEOTIDES, AND DIDEOXYRIBONUCLEOTIDES FOR AUTOMATED DNA ANALYSIS AND HOMOGENEOUS AMPLIFICATION/DETECTION ASSAYS | BAYLOR COLLEGE OF MEDICINE (US) | 1998-04-08 | — | — | EP | claimed |
| US-5728529-A | Alternative dye-labeled ribonucleotides, deoxyribonucleotides, and dideoxyribonucleotides for automated DNA analysis | BAYLOR COLLEGE OF MEDICINE (US) | 1998-03-17 | — | — | US | claimed |
| WO-1997000967-A1 | ALTERNATIVE DYE-LABELED PRIMERS, RIBONUCLEOTIDES, DEOXYRIBONUCLEOTIDES, AND DIDEOXYRIBONUCLEOTIDES FOR AUTOMATED DNA ANALYSIS AND HOMOGENEOUS AMPLIFICATION/DETECTION ASSAYS | BAYLOR COLLEGE OF MEDICINE (US) | 1997-01-09 | — | — | WO | claimed |
| US-5028525-A | Method of preparing and applying single stranded DNA probes to double stranded target DNAs in situ | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-07-02 | — | — | US | claimed |
| WO-2026098481-A1 | COMPOSITION AND USE THEREOF | 南京百斯杰生物工程有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260130404-A1 | SWEETNESS AND TASTE IMPROVEMENT OF NON-SUCROSE SWEETENERS WITH D-SUGARS OR L-SUGARS | THE COCA COLA CO (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4159050-B1 | STEVIOL GLYCOSIDE COMPOSITIONS FOR ORAL INGESTION OR USE | CARGILL INC (US) | 2026-05-13 | — | — | EP | disclosed |
| WO-1994000599-A2 | PROCESS FOR DETECTION OF NEOPLASTIC DISEASE | WHITTIER INSTITUTE FOR DIABETES AND ENDOCRINOLOGY (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0416817-A2 | Amplification processes | ZENECA LIMITED (GB) | 1991-03-13 | — | — | EP | disclosed |
| EP-0332435-A2 | Method of detecting nucleotide sequences | ZENECA LIMITED (GB) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407703-B2 | Means and methods for producing Neisseria meningitidis capsular polysaccharides of low dispersity | ENGASE, NANS, FUT5 | ENPP1 454/4885P2RY2 3147/4885P2RY4 2282/4885 |
| US-20260130404-A1 | SWEETNESS AND TASTE IMPROVEMENT OF NON-SUCROSE SWEETENERS WITH D-SUGARS OR L-SUGARS | TAS2R40, TAS2R13, TAS2R31 | ENPP1 4059/4885P2RY2 392/4885P2RY4 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.